Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting

Bermúdez, J. Amores; García, I. Osmán; Urzaiz, Miguel Unda; Marrero, P. Jiménez; Cepero, M.J. Ledo; Llarena, Roberto; Martín, J. Flores; Vivas-Pérez, José Ignacio Abad; Rodrigo-Aliaga, M.; Soto, Álvaro Juárez

doi:10.1016/j.acuroe.2019.03.010

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pattern of usage is similar to that observed in Checkmate-025 trial and other real-world experience data from Spain where patients had received only one prior antiangiogenic therapy. 16 Our study had an almost equal proportion of patients belonging to the IMDC intermediate and poor risk group and no patients in the good risk group. This was in stark contrast to the Checkmate-025 trial where a majority of patients belonged to the MSKCC good and intermediate risk group.…”

Section: Discussionmentioning

confidence: 70%

Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India

Rauthan

Murthy

Patil

et al. 2022

South Asian J Cancer

View full text Add to dashboard Cite

Introduction Nivolumab monotherapy is approved for the treatment of metastatic renal cell carcinoma (mRCC) patients who have progressed on prior therapies based on the pivotal Checkmate-025 trial. There is limited literature on the efficacy and safety profile of usage of nivolumab in the treatment of mRCC in India in a real-world setting. Methods A retrospective analysis was performed of patients who received nivolumab monotherapy for mRCC after having progressed on prior therapies. Tumor response was graded according to RECIST v1.1 and Kaplan–Meier survival analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Immune-related adverse events (irAEs) were documented and graded according to CTCAE v5.0. Results Between 2016 and 2019, 35 patients received nivolumab for mRCC at our center after progression on prior therapies. A majority of the patients (n = 30, 85.7%) received it in a second-line setting, and the remaining in the third line and beyond setting. Clear cell was the most common histology (n = 26, 74.3%). There were 18 patients (51.42%) who belonged to IMDC intermediate risk, while 17 (48.58%) patients were at poor risk. The overall response rate was 60%, with complete response (CR) in 11.4%. Median duration of response was not reached among responders. Median PFS was 5 months (95% confidence interval [CI]: 3.06–6.93) and median OS was 26 months (95% CI: 1.90–50.09). Ongoing survival of 47, 42, 34, and 22 months was noted in four patients with CR, respectively. In our study, 23 patients (65.71%) experienced any grade of irAE. Grade 3 irAEs was seen in four patients (11.42%). Most common irAE was thyroid dysfunction seen in 12 patients (34.2%). Treatment discontinuation due to irAEs occurred in three patients (8.57%). Conclusion Nivolumab showed good efficacy with high response rates and an OS comparable to the pivotal Checkmate-025 trial. It was well tolerated with safety profile in terms of irAE consistent with those reported in literature.

show abstract

Section: Discussionmentioning

confidence: 70%